Company Description
Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines.
The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform.
The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects.
All therapeutic candidates in development are based on this platform, with research and development activities focused on neuropsychiatric medicines.
The company serves clinicians and key opinion leaders in the healthcare and neuropsychiatric medicine sectors.
The company was founded in 2024 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2024 |
| IPO Date | May 1, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Daphne Zohar |
Contact Details
Address: 101 Seaport Blvd., Floor 12 Boston, Massachusetts 02210-2186 United States | |
| Phone | (617) 807-4062 |
| Website | seaporttx.com |
Stock Details
| Ticker Symbol | SPTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 2042347 |
| CUSIP Number | 81221K108 |
| ISIN Number | US81221K1088 |
| Employer ID | 99-2235719 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daphne Zohar | Founder, Chief Executive Officer, President and Director |
| Dr. Steven M. Paul M.D. | Founder and Non-Employee Chair of the Board |
| Dr. Michael Cunyuan Chen Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. Antony Loebel M.D. | Chief Medical Officer and President of Clinical Development |
| Lauren A. White M.B.A. | Chief Financial Officer |
| Lana Gladstein J.D. | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 8, 2026 | 10-Q | Quarterly Report |
| Jun 8, 2026 | 8-K | Current Report |
| May 11, 2026 | SCHEDULE 13D | Filing |
| May 11, 2026 | SCHEDULE 13G | Filing |
| May 6, 2026 | SCHEDULE 13D | Filing |
| May 4, 2026 | 8-K | Current Report |
| May 4, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 1, 2026 | 424B4 | Prospectus |
| Apr 30, 2026 | EFFECT | Notice of Effectiveness |
| Apr 30, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |